IP Library › Granted Patent US 12673030
Granted Patent B2
US 12673030 · App. 18/566,951 · Granted Jul 7, 2026

Pharmaceutical composition for burn treatment comprising TMD nanosheets as an active ingredient

Inventors: Jong-Ho Kim (Gyeonggi-do, KR); Chul-Su Yang (Gyeonggi-do, KR); Da-Bin Yim (Gyeonggi-do, KR); Yoonhee So (Gyeonggi-do, KR)
Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
A61K9/70A61K33/04A61P17/02C01G41/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673030
App. No.
18/566,951
Filed
Dec 4, 2023
Granted
Jul 7, 2026
Kind
B2
Art Unit
1612
USPC
424/443
Abstract

Provided is a pharmaceutical composition for treating burns containing transition metal dichalcogenide (TMD) as an active ingredient.

Claims (17)

1 . A pharmaceutical composition for treating burns comprising 2H-phase tungsten disulfide (2H-WS 2 ) nanosheets as an active ingredient,

wherein the 2H-WS 2 has a trigonal prismatic crystal structure, and the composition provides burn healing efficacy while exhibiting reduced cytotoxicity against normal skin cells.

2 . The pharmaceutical composition for treating burns of claim 1 , wherein the 2H-WS 2 is in the form of nanosheets having an average lateral size of 50-200 nm.

3 . The pharmaceutical composition for treating burns of claim 2 , wherein the nanosheets are exfoliated via ultrasonication.

4 . The pharmaceutical composition for treating burns of claim 3 , wherein the nanosheets are displayed in a poly(ε-caprolactone)-block-poly(ethylene glycol) (PCL-b-PEG) solution.

5 . The pharmaceutical composition for treating burns of claim 4 , wherein the composition exhibits an absorption peak in a wavelength range of 600 to 700 nm.

6 . The pharmaceutical composition for treating burns of claim 1 , wherein the composition reduces apoptosis and expresses antimicrobial peptides while exhibiting anti-inflammatory activity.

7 . The pharmaceutical composition for treating burns of claim 1 , wherein the composition enhances antioxidant enzyme activity including catalase (CAT) and glutathione peroxidase (GPx).

8 . A method for preparing pharmaceutical composition for treating burns, the method comprising: adding 2H-WS 2 to a PCL-b-PEG polymer solution; ultrasonically treating the added solution; and obtaining a composition from a supernatant of the ultrasonically treated solution.

9 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the 2H-WS 2 nanosheets have a trigonal prismatic phase.

10 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 1 .

11 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 2 .

12 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 3 .

13 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 4 .

14 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 5 .

15 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 6 .

16 . The method for preparing pharmaceutical composition for treating burns of claim 8 , wherein the composition is the pharmaceutical composition for treating burns of claim 7 .